Assessment of cyto/genotoxicity of irinotecan in V79 cells using the comet, micronucleus, and chromosome aberration assay

Arhiv za Higijenu Rada i Toksikologiju

Volumn 61, Issue 1, 2010, Pages 1-9

  Kašuba, Vilena ^a   Rozgaj, Ružica ^a   Gamulin, Marija ^b   Trošić, Ivančica ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Alkaline comet assay; Antineoplastic drug; Cell cultures; DNA and cytogenetic damage

Indexed keywords

DNA; IRINOTECAN;

ANALYSIS OF VARIANCE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN V 79; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; COMET ASSAY; CYTOTOXICITY; DOSE RESPONSE; GENOTOXICITY; MICRONUCLEUS TEST; MONOTHERAPY; NONHUMAN; RANK SUM TEST; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE; CELLS, CULTURED; CHROMOSOME ABERRATIONS; COMET ASSAY; CRICETINAE; CRICETULUS; MICRONUCLEUS TESTS; MUTAGENICITY TESTS;

EID: 77950210647     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: 10.2478/10004-1254-61-2010-1967     Document Type: Article

References (34)

1. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878
2. Hsiang YH, Liu LF. Identifi cation of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-1726
3. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-4638
4. Kjeldsen E, Svejstrup JQ, Gromova H, Alsner J, Westergaard O. Camptothecin inhibits both the cleavage and religation reactions of eucaryotic DNA topoisomerase I. J Mol Biol 1992;228:1025-1030
5. Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003;45:91-108.
6. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-760
7. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291
8. Rothenberg ML, Kuhn JG, Schaf LJ, Drengler RL, Eckhardt SG, Villalonacalero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Vonhoff DD. Alternative dosing scheduels for Irinotecan. Oncology (Huntington) 1998;12(Suppl 6):68-71.
9. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972;32:2643-2650
10. Irinotecan. USP DI. Vol.1, Drug information for the health care professional. 20th ed. Englewood (CO): Micromedex Inc.; 2000.
11. Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantifi cation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191
12. Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS. Preclinical and clinical results with Irinotecan - extending principles learned in model system to clinical trails design. Oncology (Williston Park). 1998;12(8 Suppl 6):84-93.
13. Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 1993;84:566-573
14. Kopjar N, Ẑeljeẑć D, Lucić Vrdoljak A, Radić B, Ramić S, Milić M, Gamulin M, Pavlica V, Fućić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol 2007;100:403-413
15. Sanchez-Alcazar JA, Bradbury DA, Brea-Calvo G, Navas P, Knox AJ. Camptothecin-induced apoptosis in non-small cell lung cancer is independent on cyclooxygenase expression. Apoptosis 2003;8:639-647
16. Ciesielski MJ, Fenstermaker RA. Synergistic cytotoxicity, apoptosis and protein linked DNA breakage by etoposiDe and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorilation. J Neurooncol 1999;41:223-234
17. Minderman H, Conroy JM, O Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. In vitro and in vivo irinotecan-induced changes in expression profi les of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Therap 2005;4:885-900.
18. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anti-Cancer Drugs 2001;12:741-751
19. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroentrol Hepatol 2003;18:1095-1100
20. Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-2757
21. Daza P, Torreblanca J, Garcia-Herdugo G, Moreno FJ. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells. Cell Biol Int 2002;26:707-713
22. Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002;520:47-56.
23. Gradzka I, Skierski J, Szumiel I. DNA repair, cell cycle progression and cell death following Camptothecin treatment in two murine lymphoma L5178Y sublines. Cell Biochem Funct 1998;16:239-252
24. Ollikainen T, Knuuttila A, Suhonen S, Taavitsainen M, Jekunen A, Mattson K, Linnainmaa K. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs 2000;11:93-99
25. Anderson RD, Berger NA. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994;309:109-142
26. Voight W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM. Topoisomerase- I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 1998;18(5A):3499-3505
27. Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;193:27-35.
28. Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52:1823-1829
29. Mahabir AG, Benthem Jv, Korsten H, Lynch AM, Bailey L, De Vries A, Hendriksen CF, Van Steeg H. Detecting genotoxic effects of potential clastogens: An in vivo study using the transgenic lacZ plasmid and the MutaTM Mouse model. Mutat Res 2008;652:151-157
30. Holmstrom M, Winters V. Micronuclei induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice. Mutagenesis 1992;7:189-193
31. Bacher LC, Allen JW, Harrington-Brock K, Campbell JA, Moore MM. Genotoxicity of inhibitors of DNA topoisomerase I (camptothecin) and II (m-ASA) in vivo and in vitro. Mutagenesis 1990;5:541-547
32. Hardman WE, Moyer MP, Cameron IL. Consumption of an omege-3 fatty acids product, INCELL AAFATM, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983-988
33. Aydemir N, Bilaloglu R. Genotoxicity of two anticancer drugs; gentamicine and topotecan, in mouse bone marrow in vivo. Mutat Res 2003;537:43-51.
34. Attia SM, Aleisa AM, Bakheet SA, Al-Yahya AA, Al-Reyaie SS, Ashour AE, Al-Shabanah OA. Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan and irinotecan. Environ Mol Mutegen 2009;50:145-151